Skip to search formSkip to main contentSkip to account menu

brofaromine

Known as: 4-(5-methoxy-7-bromobenzofuranyl)-2-piperidine, Piperidine, 4-(7-bromo-5-methoxy-2-benzofuranyl)-, hydrochloride, brofaromin 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

CGP 11305Abrofaromine hydrochloride

Broader (2)

Monoamine Oxidase InhibitorsPiperidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Post-traumatic stress disorder.
INTRODUCTION Post-traumatic stress disorder (PTSD) may affect 10% of women and 5% of men at some stage, and symptoms may persist… 
2005
2005
Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers
The present study compared the extent and duration of MAO inhibition by the selective and reversible MAO-A inhibitor brofaromine… 
Review
1997
Review
1997
New uses for antidepressants: social phobia.
Data from recent epidemiologic surveys of community populations indicate that social phobia is a common psychiatric disorder and… 
1996
1996
MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients A preliminary report
Abstract Little is known about biological predictors of treatment response in panic disorder (PD). In the present study heart… 
1994
1994
Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behavior and mood rating scores in brofaromine-treated women with bulimia nervosa.
Women with bulimia nervosa undergoing treatment with the reversible monoamine oxidase type A inhibitor, brofaromine, were rated… 
1993
1993
Role of cytochrome P4502D6 in the metabolism of brofaromine
SummaryThe metabolic fate of brofaromine (CGP 11 305 A), a new, reversible, selective MAO-A inhibitor, has been assessed in poor… 
1993
1993
Treatment of narcolepsy‐cataplexy syndrome with the new selective and reversible MAO‐A inhibitor brofaromine—a pilot study
SUMMARY  Eighteen narcoleptic patients were treated in a single‐blind study with brofaromine, a new selective and reversible MAO… 
Review
1993
Review
1993
Clinical pharmacology of reversible monoamine oxidase-A inhibitors.
Traditional monoamine oxidase inhibitors (MAOIs) have long been associated with tyramine-related hypertension--the cheese effect… 
1990
1990
Brofaromine (CGP 11 305 A) in Treatment of Depression:Biological Estimation of Plasma Concentrations
In an open clinical trial, 13 depressives were treated with the reversible and selective type-A monoamine oxidase (MAO)-inhibitor… 
1989
1989
[Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
The rat studies presented in this manuscript show that the new non-hydrazine compounds moclobemide, brofaromine and toloxatone… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)